Nabriski, Dan
University of Nebraska Medical Center
3 papers on CoChat
Most cited papers
- Verified
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 850
- Verified
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 351
- Verified
Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese.
Ness‐Abramof, R., Nabriski, D., Apovian, C. M., Niven, M., Weiss, E., Shapiro, M. S., & Shenkman, L. (2002) · Obesity Research
Pituitary Gland Disorders and TreatmentsAdrenal and Paraganglionic Tumors
Cited by 58
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free